NCT07296627

Real-world Immuno-therapy in Chinese Newly Diagnosed Multiple Myeloma Patients

A Prospective Study for Chinese Newly Diagnosed Multiple Myeloma Patients Treated With Immuno-therapy in Real-world Setting

• Status: Recruiting
• Phase: —
• Study type: Observational
• Enrollment: 500 (estimated)
• Sponsor: Peking University People's Hospital · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

To conduct a multicenter, prospective observational cohort study to investigate first-line immunotherapy patterns and clinical outcomes in NDMM patients in China. Leveraging the extensive patient resources of China's large center for blood disorders, the investigator will recruit approximately 500 NDMM patients to establish an NDMM patient cohort. The investigator will collect data on disease characteristics, treatment patterns, and clinical outcomes through one year of clinical follow-up. Further long-term follow-up is needed to obtain survival status and causes of death, so as to provide essential evidence for optimizing and improving patients' prognosis in clinical individualized treatment.

Conditions

• Newly Diagnosed Multiple Myeloma (NDMM)

Timeline

• Start date: 2025-07-16
• Primary completion: 2027-07-15
• Completion: 2027-11-15
• First posted: 2025-12-22
• Last updated: 2025-12-22

Locations

1 site across 1 country: China